David Hunt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David Hunt has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
Sarah McGlasson
Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK
7 shared publications- Sarah McGlasson
Centre for Clinical Brain Sciences, University of Edinburgh , Edinburgh EH16 4SB
5 shared publications - Aziz Sheikh
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
4 shared publications - Bastien Rioux
University of Edinburgh
4 shared publications Carol A. C. Coupland
Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK
4 shared publicationsDeborah Forbes
Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK; UK DRI University of Edinburgh, Edinburgh, UK
4 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (8) , e612-e624
Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study
- 2 July 2026
- Published by Elsevier in The Lancet Rheumatology
- Vol. 8 (8) , e612-e624
Open AccessInterferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study
- Open Access
- 27 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Oligoprotein type I interferon signatures, but not TREX1 variants, increase risk of systemic lupus erythematosus in UK Biobank
The 3′ − 5′ DNA exonuclease, TREX1, is a negative regulator of the type I interferon response, while TREX1 variants are considered to confer risk for non-monogenic systemic lupus erythematosus (SLE). Here we analyse TREX1 sequences in 469,229 UK Biobank participants together with multi-omics data from the UK Biobank Pharma Proteomics Project to reappraise the contribution of reported TREX1 risk variants in SLE. We find that TREX1 variants are not associated with increased risk for SLE in UK Biobank, and most reported risk variants are functionally neutral in mutagenesis experiments. Deriving an oligoprotein interferon signature from broad capture proteomics, we find that this signature is associated with elevated SLE risk, but is not elevated in TREX1 variant carriers. Furthermore, TREX1 variants are not associated with other autoimmune diseases with a prominent oligoprotein interferon signature. Finally, meta-analysis of published studies confirms the lack of support for the association between SLE and TREX1 risk variants. In summary, we find that, while oligoprotein type I interferon signatures increase risk of SLE, TREX1 variants do not.
- 27 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessOligoprotein type I interferon signatures, but not TREX1 variants, increase risk of systemic lupus erythematosus in UK Biobank
The 3′ − 5′ DNA exonuclease, TREX1, is a negative regulator of the type I interferon response, while TREX1 variants are considered to confer risk for non-monogenic systemic lupus erythematosus (SLE). Here we analyse TREX1 sequences in 469,229 UK Biobank participants together with multi-omics data from the UK Biobank Pharma Proteomics Project to reappraise the contribution of reported TREX1 risk variants in SLE. We find that TREX1 variants are not associated with increased risk for SLE in UK Biobank, and most reported risk variants are functionally neutral in mutagenesis experiments. Deriving an oligoprotein interferon signature from broad capture proteomics, we find that this signature is associated with elevated SLE risk, but is not elevated in TREX1 variant carriers. Furthermore, TREX1 variants are not associated with other autoimmune diseases with a prominent oligoprotein interferon signature. Finally, meta-analysis of published studies confirms the lack of support for the association between SLE and TREX1 risk variants. In summary, we find that, while oligoprotein type I interferon signatures increase risk of SLE, TREX1 variants do not.
- 22 January 2026
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (2) , 121-122
The potential for dementia prevention through vaccination
- 22 January 2026
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (2) , 121-122
The potential for dementia prevention through vaccination
- Open Access
- 7 October 2025
- Published by Springer Nature
Predictors of disease activity in multiple sclerosis
- 7 October 2025
- Published by Springer Nature
Open AccessPredictors of disease activity in multiple sclerosis
- Open Access
Decades-long elevation of interferon-α drives a Sjögren disease endotype: an interdisciplinary study
SUMMARY: BACKGROUND: Mechanistic heterogeneity is a major obstacle to the development of effective treatment for Sjögren disease (SjD) and there is a pressing need to stratify SjD according to precision medicine principles. Aberrant activation of the type I interferon (IFN) pathway represents a leading candidate pathway, but a causal role of elevated IFN-α in driving a Sjögren disease endotype remains to be established. METHODS: We used ultrasensitive single molecule ELISA, and an oligoprotein interferon signature score (derived from broad capture proteomics), to study the role of IFN-α in Sjögren disease. We analysed samples from the UK Primary Sjögren Syndrome Registry (UKPSSR, n=177) and UK Biobank Plasma Proteomics Project (n=47606 without Sjögren, n=257 with Sjögren, including 137 individuals sampled prior to diagnosis) to determine the timecourse and immune endotype associated with elevated IFN-α. To address causality we created a new transgenic mouse model of IFN-α overexpression to establish whether chronically elevated IFN-α drives this immune endotype. FINDINGS: Oligoprotein interferon signatures can be detected at least 14 years prior to diagnosis of Sjögren disease in the UK Biobank-PPP. IFN-α concentrations are elevated in 60% of Sjögren disease patients in the UKPSSR. Individuals with elevated IFN-α display a distinct immunological endotype characterised by cytopenias, hypergammaglobulinaemia, multiple autoantibodies and autoimmunity against the Sjögren autoantigen TRIM21/Ro52. To address the key question of causal direction, we created a new mouse model of systemic chronic IFN-α elevation, in which Ifn α 4 is overexpressed by conventional dendritic cells. This model recapitulates key features of the endotype and can be partially reversed by IFNAR1 blockade. INTERPRETATION: Elevation of IFN-α drives an immune endotype of Sjögren disease, originating over a decade prior to diagnosis. SjD patients with elevated IFN-α concentrations are broadly clinically similar to those with normal IFN-α concentrations, yet are immunologically distinct. This highlights the mechanistic heterogeneity of SjD and the need for immunological stratification along precision medicine principles, using high resolution biomarkers. As well as demonstrating causal direction, biological modelling shows that chronic IFN-α elevation over the lifecourse has the potential to establish persistent immune dysregulation which responds only partially to interferon receptor blockade. These findings provide insights into SjD and other “interferonopathic” rheumatological disorders. Research in context: Evidence before this study: We searched MEDLINE for “Sjögren’s Syndrome/Disease” and “interferon”, including the terms “subsets”, “sub-groups”, “phenotypes”, and “endotypes”, filtering by “clinical trial”, “stratification”, and “immune-mediated inflammatory”. We also included major review articles from noted experts. We identified reports of associations between IFN-α and SjD, usually using indirect or imprecise measures of IFN-α. None of these studies included prediagnostic samples and causal inference was limited. Added value of this study: This study shows that IFN-α, when measured directly using ultrasensitive single molecule ELISA approaches (uniquely optimised to determine healthy control concentrations), is elevated in a subset of people with SjD with a specific immunological endotype. Analysis of prediagnostic proteomics shows this elevation can be detected up to 14 years before diagnosis. We show that IFN-α drives this endotype (as opposed to vice versa) by recapitulating key endotype features in a novel and unambiguous experimental mouse model of chronic IFN-α elevation. We also show that the pathogenic consequences of IFN-α elevation over long periods of time can only be partially reversed using IFNAR blockade. Implications of all the available evidence: These data have important implications for future research, clinical practice, trial design, and therapeutic development. First, our findings provide clinical evidence, supported by unambiguous preclinical evidence, that decades-long elevated IFNα can cause and drive a SjD endotype – and accurately defines the level of heterogeneity. Secondly, we provide biomarkers which may be of use in stratifying clinical trial design and also for early identification of at-risk individuals. Thirdly we provide biological proof of principle that longstanding and potentially undiagnosed elevation of IFN-α can establish persistent immune dysregulation which may respond only partially to IFNAR blockade. Together these findings inform precision medicine approaches and future trial design.
Open AccessDecades-long elevation of interferon-α drives a Sjögren disease endotype: an interdisciplinary study
SUMMARY: BACKGROUND: Mechanistic heterogeneity is a major obstacle to the development of effective treatment for Sjögren disease (SjD) and there is a pressing need to stratify SjD according to precision medicine principles. Aberrant activation of the type I interferon (IFN) pathway represents a leading candidate pathway, but a causal role of elevated IFN-α in driving a Sjögren disease endotype remains to be established. METHODS: We used ultrasensitive single molecule ELISA, and an oligoprotein interferon signature score (derived from broad capture proteomics), to study the role of IFN-α in Sjögren disease. We analysed samples from the UK Primary Sjögren Syndrome Registry (UKPSSR, n=177) and UK Biobank Plasma Proteomics Project (n=47606 without Sjögren, n=257 with Sjögren, including 137 individuals sampled prior to diagnosis) to determine the timecourse and immune endotype associated with elevated IFN-α. To address causality we created a new transgenic mouse model of IFN-α overexpression to establish whether chronically elevated IFN-α drives this immune endotype. FINDINGS: Oligoprotein interferon signatures can be detected at least 14 years prior to diagnosis of Sjögren disease in the UK Biobank-PPP. IFN-α concentrations are elevated in 60% of Sjögren disease patients in the UKPSSR. Individuals with elevated IFN-α display a distinct immunological endotype characterised by cytopenias, hypergammaglobulinaemia, multiple autoantibodies and autoimmunity against the Sjögren autoantigen TRIM21/Ro52. To address the key question of causal direction, we created a new mouse model of systemic chronic IFN-α elevation, in which Ifn α 4 is overexpressed by conventional dendritic cells. This model recapitulates key features of the endotype and can be partially reversed by IFNAR1 blockade. INTERPRETATION: Elevation of IFN-α drives an immune endotype of Sjögren disease, originating over a decade prior to diagnosis. SjD patients with elevated IFN-α concentrations are broadly clinically similar to those with normal IFN-α concentrations, yet are immunologically distinct. This highlights the mechanistic heterogeneity of SjD and the need for immunological stratification along precision medicine principles, using high resolution biomarkers. As well as demonstrating causal direction, biological modelling shows that chronic IFN-α elevation over the lifecourse has the potential to establish persistent immune dysregulation which responds only partially to interferon receptor blockade. These findings provide insights into SjD and other “interferonopathic” rheumatological disorders. Research in context: Evidence before this study: We searched MEDLINE for “Sjögren’s Syndrome/Disease” and “interferon”, including the terms “subsets”, “sub-groups”, “phenotypes”, and “endotypes”, filtering by “clinical trial”, “stratification”, and “immune-mediated inflammatory”. We also included major review articles from noted experts. We identified reports of associations between IFN-α and SjD, usually using indirect or imprecise measures of IFN-α. None of these studies included prediagnostic samples and causal inference was limited. Added value of this study: This study shows that IFN-α, when measured directly using ultrasensitive single molecule ELISA approaches (uniquely optimised to determine healthy control concentrations), is elevated in a subset of people with SjD with a specific immunological endotype. Analysis of prediagnostic proteomics shows this elevation can be detected up to 14 years before diagnosis. We show that IFN-α drives this endotype (as opposed to vice versa) by recapitulating key endotype features in a novel and unambiguous experimental mouse model of chronic IFN-α elevation. We also show that the pathogenic consequences of IFN-α elevation over long periods of time can only be partially reversed using IFNAR blockade. Implications of all the available evidence: These data have important implications for future research, clinical practice, trial design, and therapeutic development. First, our findings provide clinical evidence, supported by unambiguous preclinical evidence, that decades-long elevated IFNα can cause and drive a SjD endotype – and accurately defines the level of heterogeneity. Secondly, we provide biomarkers which may be of use in stratifying clinical trial design and also for early identification of at-risk individuals. Thirdly we provide biological proof of principle that longstanding and potentially undiagnosed elevation of IFN-α can establish persistent immune dysregulation which may respond only partially to IFNAR blockade. Together these findings inform precision medicine approaches and future trial design.
- Open Access
- 6 June 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (8) , 2981-2994
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is an incurable microvascular disease caused by C-terminus truncation of the TREX1 exonuclease. There is a pressing need to understand disease mechanisms and identify therapeutic targets. We evaluated TREX1 sequencing data from 469 229 UK Biobank participants together with RVCL-S-related microvascular clinical and imaging outcomes. We show that mono-allelic truncating mutations in TREX1 require intact nuclease activity in order to cause endothelial disease. Differential proteomics identifies loss of interaction with endoplasmic reticulum insertion proteins such as Guided Entry of Tail-Anchored Proteins Factor 3 as a major consequence of pathogenic TREX1 truncation, and this altered trafficking results in the unregulated presence of enzymatically active TREX1 in the nucleus. In endothelial cells with a patient mutation, mislocalized yet enzymatically active TREX1 causes accumulation of a spectrum of DNA damage. These pathological changes can be rescued by inhibiting exonuclease activity. In summary, our data implicate exonuclease-dependent DNA damage in endothelial cells as a key therapeutic target in the pathogenesis of RVCL-S.
- 6 June 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (8) , 2981-2994
Open AccessMisdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is an incurable microvascular disease caused by C-terminus truncation of the TREX1 exonuclease. There is a pressing need to understand disease mechanisms and identify therapeutic targets. We evaluated TREX1 sequencing data from 469 229 UK Biobank participants together with RVCL-S-related microvascular clinical and imaging outcomes. We show that mono-allelic truncating mutations in TREX1 require intact nuclease activity in order to cause endothelial disease. Differential proteomics identifies loss of interaction with endoplasmic reticulum insertion proteins such as Guided Entry of Tail-Anchored Proteins Factor 3 as a major consequence of pathogenic TREX1 truncation, and this altered trafficking results in the unregulated presence of enzymatically active TREX1 in the nucleus. In endothelial cells with a patient mutation, mislocalized yet enzymatically active TREX1 causes accumulation of a spectrum of DNA damage. These pathological changes can be rescued by inhibiting exonuclease activity. In summary, our data implicate exonuclease-dependent DNA damage in endothelial cells as a key therapeutic target in the pathogenesis of RVCL-S.
- 7 August 2024
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (9) , 541-554
Identifying and reducing risks of neurological complications associated with vaccination
Vaccines protect against many infectious diseases, including some that can directly or indirectly cause nervous system damage. Serious neurological consequences of immunization are typically extremely rare, although they have the potential to jeopardize vaccination programmes, as demonstrated most recently during the COVID-19 pandemic. Neurologists have an important role in identifying safety signals at population and individual patient levels, as well as providing advice on the benefit–risk profile of vaccination in cohorts of patients with diverse neurological conditions. This article reviews the links between vaccination and neurological disease and considers how emerging signals can be evaluated and their mechanistic basis identified. We review examples of neurotropic infections with live attenuated vaccines, as well as neuroimmunological and neurovascular sequelae of other types of vaccines. We emphasize that such risks are typically dwarfed by neurological complications associated with natural infection and discuss how the risks can be further mitigated. The COVID-19 pandemic has highlighted the need to rapidly identify and minimize neurological risks of vaccination, and we review the structures that need to be developed to protect public health against these risks in the future.
- 7 August 2024
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (9) , 541-554
Identifying and reducing risks of neurological complications associated with vaccination
Vaccines protect against many infectious diseases, including some that can directly or indirectly cause nervous system damage. Serious neurological consequences of immunization are typically extremely rare, although they have the potential to jeopardize vaccination programmes, as demonstrated most recently during the COVID-19 pandemic. Neurologists have an important role in identifying safety signals at population and individual patient levels, as well as providing advice on the benefit–risk profile of vaccination in cohorts of patients with diverse neurological conditions. This article reviews the links between vaccination and neurological disease and considers how emerging signals can be evaluated and their mechanistic basis identified. We review examples of neurotropic infections with live attenuated vaccines, as well as neuroimmunological and neurovascular sequelae of other types of vaccines. We emphasize that such risks are typically dwarfed by neurological complications associated with natural infection and discuss how the risks can be further mitigated. The COVID-19 pandemic has highlighted the need to rapidly identify and minimize neurological risks of vaccination, and we review the structures that need to be developed to protect public health against these risks in the future.
- Open Access
- 8 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1
Author Correction: Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
- 8 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1
Open AccessAuthor Correction: Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
- Open Access
- 27 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 3822
Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0–5) and 5 (95%CI 3–6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0–23) hospitalisations with epilepsy and 4 (95%CI 0–6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.
- 27 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 3822
Open AccessSafety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0–5) and 5 (95%CI 3–6) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0–23) hospitalisations with epilepsy and 4 (95%CI 0–6) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.